Objective: Atrial fibrillation (AF) is an important health problem in Turkey. However, no prospective, multicenter, large trial reflecting national data has been published so far. Therefore, the aim of this study was to follow, analyze and evaluate patients with AF in a large multicenter nation-wide trial. Methods: Two thousand three hundred consecutive patients with AF in their electrocardiogram, reflecting all the population of seven geographical regions of Turkey will be included in the study. The patients will be followed up for two years and death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding, hospitalization will be recorded as the primary end-point. Results: Will be available at the end of the study; preliminary results will be due December 2012. Conclusion: General risk profile of patients with AF, frequency of anticoagulation, frequency of effective treatment and risks of bleeding will be evaluated according to the current guidelines. Major adverse events and their independent predictors will be determined. (Anadolu Kardiyol Derg 2013; 13: 339-43) 
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence of 1 to 2% in the general population (1) . AF leads to an increase in the risk of stroke by five times and one fifth of all strokes occur on a background of arrhythmia. The mortality, morbidity and recurrence rates of AF-related strokes are higher than other causes (2) . According to the results of the TEKHARF (Cardiac Diseases and Risk Factors in Adults in Turkey) study, the prevalence of AF in our country is 1.25% and its overall morbidity is 6.8/100 person-year (3) It is obvious that AF is a significant health problem in our country. While there are many studies assessing the epidemiological data concerning the use of oral anticoagulant medication in patients with AF (4) (5) (6) (7) (8) , single center studies on the anticoagulant therapy and the risk of cerebrovascular event have been conducted in our country (9) (10) (11) .
However, no prospective, multicenter study on a scale reflecting the epidemiology of the country was conducted in our country.
In the multicenter Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER) study, we will prospectively examine the extent and epidemiological characteristics of the patients with AF.
Methods
Study design, sample size AFTER study is planned as a prospective, observational and multicenter study and a 2-year follow-up of the patients.
In the anticipation of a total of 310 deaths and 650 events with a death rate of 6.8 and approximately 15 combined events per 100 person/year will be necessary for the multivariate logistic regression analysis intended to find out the independent indicators of the major adverse events. The follow up of 2300 patients for two years is calculated to be adequate. According to the data provided by the Turkish Statistical Institution, 2300 patients reflecting the population of the seven regions of our country will be included in the study.
Sample representation
First of all, all the tertiary centers from seven geographical areas were invited to participate. A sample representing the population of that geographical area was measured. After agreement, these centers were interviewed and informed about the number of the patients that they shall admit in the study according to the population of the area. The numbers of the patients included in the study according to the regions are shown in Figure 1 . Overall, 17 tertiary health care centers agreed to participate in the study. The names and coordinators are shown in Table 1 .
Algorithm of the trial
The main steps of the procedures are shown in Figure 2 . The inclusion criteria will determine which patients are eligible for the participation to the study. The inclusion criteria are determined as "all consecutive patients over 18 years of age who applied to the cardiology outpatient clinics with at least one attack of AF identified on electrocardiographic examination". Emergency admittances, inpatients, patients who refuse to be included in the study or do not sign the consent form will be excluded from the study. The standard registration form shown in Figure 3 will be filled out for each patient and the patients will sign a consent form.
Ethical considerations
Ethics Committee consent of the study coordinating center was obtained (The Ethics Committee of the University of Dicle; 28/3/2012-491). Every patient will sign a consent form.
Trial outcomes
Primary outcome considered is the major cardiac endpoints (death, transient ischemic attack, stroke, systemic thromboembolism, major hemorrhage and hospital admission). In addition, the medication condition of the patients will also be assessed. The inclusion of the patients in the study will be started in April 2012 and the date of the achievement of the targeted number of patients will be the ending date.
Definitions and measurements
The basic demographic data and medical treatments of the patients will be evaluated. The evaluation of the patient will be performed by a cardiologist and the data obtained will be recorded in a patient registration form prepared for the study. The stroke risk will be assessed by CHA2DS2-VASc score (12) and the bleeding risk will be assessed by the HAS-BLED score (13) . CHA2DS2-VASc depends on a point scoring system that gives 2 points for stroke or transient ischemic attack and age ≥75 years and 1 point for each of the following factors: age between 65 and 74 years, history of hypertension, diabetes, recent cardiac failure, vascular disease (Myocardial infarction, complex aortic plaque, prior revascularization, amputation due to peripheral artery disease or peripheral artery disease including angiographic findings) and female gender (12) . Hypertension, abnormal renal/liver function, stroke, history of bleeding or tendency to bleeding, labile INR, advanced age (>65), concomitant drugs/ alcohol are the parameters used in the calculation of HAS-BLED bleeding risk score (13) . The routine electrocardiographic examination of the patients will be performed with regards to cardiac failure. Hypertension is described as blood pressure measurement >140/90 mmHg, prior diagnosis of hypertension or being on antihypertensive treatment. Diabetes Mellitus was described as a fasting blood glucose level of >126 mg, prior diagnosis of diabetes or being on antidiabetic treatment.
The routine total blood count parameters, INR values, biochemical and thyroid function tests of the patients will be performed in each center's own laboratory. Optimal INR will be accepted as 2.0 to 3.0 as recommended by the guidelines (2). 
Statistical analysis
Statistical Package for Social Sciences software (SPSS 12, Chicago, IL, USA) will be used for the data analysis. Normality analyses will be assessed using Kolmogorov-Smirnov and Shapiro-Wilks methods and data consistent with a normal distribution will be given as mean ± standard deviation and data inconsistent with a normal distribution will be given as median (minimum-maximum). In the comparison of quantitative data; normally distributed parameters will be compared between the two groups using the Student t-test and a one sided variance analysis (ANOVA) will be used in the comparison of more than two groups. The abnormally distributed parameters will be compared between two groups using Mann-Whitney U test and the Kruskal-Wallis test will be used in the comparison of more than two groups. The Chi-square test will be used for the comparison of qualitative data. Pearson test will be used in the correlation of the numeric variables and the Spearmen test will be used for the categorical variables. A multivariate logistic regression analysis will be used for the determination of the independent indicators of the primary endpoints, Kaplan's graphics and Cox hazard proportional analysis will be used for the survival analysis at the end of the study. A p value of <0.05 will be considered significant.
Discussion Expected Benefit
In accordance with the recommendations of guidelines, the overall risk profile of the patients with AF in our country, the rates for the use of oral anticoagulant therapy and whether the targeted INR values are achieved or not and the bleeding risks of the patients will be determined in the AFTER study. At the end of the study, by detecting the prevalence of the major adverse events in patients with AF and the independent indicators of these events, the information directed to the clinical practice will be obtained, as well as a contribution will be provided to the literature.
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